Literature DB >> 15962526

Erlotinib hydrochloride.

John D Minna1, Jonathan Dowell.   

Abstract

Erlotinib hydrochloride (Tarceva; OSI Pharmaceuticals/Genentech/Roche), a member of a class of targeted anticancer drugs that inhibit the activity of the epidermal growth factor receptor, was approved by the US FDA in November 2004 for the treatment of advanced non-small-cell lung cancer after failure of at least one prior chemotherapy regimen. It is the first such drug to demonstrate an increase in survival in Phase III trials in patients with advanced non-small-cell lung cancer.

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 15962526     DOI： 10.1038/nrd1612

Source DB:  PubMed          Journal:  Nat Rev Drug Discov        ISSN： 1474-1776            Impact factor:   84.694


  11 in total

1.  Erlotinib hydro-chloride: an anti-cancer agent.

Authors:  S Selvanayagam; B Sridhar; K Ravikumar
Journal:  Acta Crystallogr Sect E Struct Rep Online       Date:  2008-04-30

2.  Identification of novel kinase targets for the treatment of estrogen receptor-negative breast cancer.

Authors:  Corey Speers; Anna Tsimelzon; Krystal Sexton; Ashley M Herrick; Carolina Gutierrez; Aedin Culhane; John Quackenbush; Susan Hilsenbeck; Jenny Chang; Powel Brown
Journal:  Clin Cancer Res       Date:  2009-10-06       Impact factor: 12.531

3.  Combination of ruthenium(II)-arene complex [Ru(η6-p-cymene)Cl2(pta)] (RAPTA-C) and the epidermal growth factor receptor inhibitor erlotinib results in efficient angiostatic and antitumor activity.

Authors:  Robert H Berndsen; Andrea Weiss; U Kulsoom Abdul; Tse J Wong; Patrick Meraldi; Arjan W Griffioen; Paul J Dyson; Patrycja Nowak-Sliwinska
Journal:  Sci Rep       Date:  2017-02-22       Impact factor: 4.379

4.  [NP protocol taken for pulmonary sarcomatoid carcinoma: a case report].

Authors:  Yang Jiao; Chong Bai
Journal:  Zhongguo Fei Ai Za Zhi       Date:  2011-06

5.  A murine model of dry eye induced by topical administration of erlotinib eye drops.

Authors:  Qi-Chen Yang; Jing Bao; Cheng Li; Gang Tan; An-Hua Wu; Lei Ye; Lin-Hong Ye; Qiong Zhou; Yi Shao
Journal:  Int J Mol Med       Date:  2017-12-29       Impact factor: 4.101

6.  Identification of MMP1 as a potential gene conferring erlotinib resistance in non-small cell lung cancer based on bioinformatics analyses.

Authors:  Huyue Zhou; Qiumei Xiang; Changpeng Hu; Jing Zhang; Qian Zhang; Rong Zhang
Journal:  Hereditas       Date:  2020-07-23       Impact factor: 3.271

7.  ZC3H15 promotes glioblastoma progression through regulating EGFR stability.

Authors:  Jianbing Hou; Minghao Xu; Hongyu Gu; Dakun Pei; Yudong Liu; Pan Huang; Hongbo Chang; Hongjuan Cui
Journal:  Cell Death Dis       Date:  2022-01-13       Impact factor: 8.469

Review 8.  Molecular mechanisms of cardiotoxicity induced by ErbB receptor inhibitor cancer therapeutics.

Authors:  Anne-Sophie Hervent; Gilles W De Keulenaer
Journal:  Int J Mol Sci       Date:  2012-09-26       Impact factor: 5.923

9.  Knockdown of β-catenin with dicer-substrate siRNAs reduces liver tumor burden in vivo.

Authors:  Henryk Dudek; Darren H Wong; Rokhand Arvan; Anee Shah; Kathleen Wortham; Bo Ying; Rohan Diwanji; Wei Zhou; Benjamin Holmes; Hailin Yang; Wendy A Cyr; Yi Zhou; Aalok Shah; Ruchir Farkiwala; Michael Lee; Yiting Li; Garrett R Rettig; Michael A Collingwood; Sujit K Basu; Mark A Behlke; Bob D Brown
Journal:  Mol Ther       Date:  2013-10-03       Impact factor: 11.454

10.  Rechallenge with erlotinib in osimertinib-resistant lung adenocarcinoma mediated by driver gene loss: a case report.

Authors:  Lingli Liu; Analyn Lizaso; Xinru Mao; Nong Yang; Yongchang Zhang
Journal:  Transl Lung Cancer Res       Date:  2020-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.